MENU
+Compare
RXST
Stock ticker: NASDAQ
AS OF
Aug 15, 02:16 PM (EDT)
Price
$8.35
Change
+$0.13 (+1.58%)
Capitalization
336.33M

RXST stock forecast, quote, news & analysis

RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery... Show more

RXST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. RXST showed earnings on August 07, 2025. You can read more about the earnings report here.
Interact to see
Advertisement
A.I.Advisor
a Summary for RXST with price predictions
Aug 14, 2025

RXST's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for RXST turned positive on July 25, 2025. Looking at past instances where RXST's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RXST's RSI Oscillator exited the oversold zone, of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on August 13, 2025. You may want to consider a long position or call options on RXST as a result. In of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where RXST advanced for three days, in of 237 cases, the price rose further within the following month. The odds of a continued upward trend are .

RXST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RXST declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for RXST entered a downward trend on July 18, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.210) is normal, around the industry mean (59.733). P/E Ratio (0.000) is within average values for comparable stocks, (38.608). RXST's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.698). RXST has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.020). P/S Ratio (2.256) is also within normal values, averaging (92.794).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. RXST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RXST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Boston Scientific Corp (NYSE:BSX), Medtronic plc (NYSE:MDT), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 5.54B. The market cap for tickers in the group ranges from 1.86K to 225.01B. ABT holds the highest valuation in this group at 225.01B. The lowest valued company is CSAY at 1.86K.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was 8%. For the same Industry, the average monthly price growth was 8%, and the average quarterly price growth was 8%. TRIB experienced the highest price growth at 114%, while MYO experienced the biggest fall at -45%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was 149%. For the same stocks of the Industry, the average monthly volume growth was 168% and the average quarterly volume growth was 144%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 77
Price Growth Rating: 62
SMR Rating: 88
Profit Risk Rating: 92
Seasonality Score: -19 (-100 ... +100)
View a ticker or compare two or three
RXST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry MedicalNursingServices

Profile
Fundamentals
Details
Industry
N/A
Address
100 Columbia
Phone
+1 949 521-7830
Employees
374
Web
https://www.rxsight.com